![Firm to continue pimavanserin PDP program but postpones trials in AD psychosis and schizophrenia. [© fred goldstein - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Oct28_2010_297555_OldManInWheelchairWithNurse_BiovailEndsAcadiaParkinsonCollab3519081126-218x150.jpg "Parkinson’s Disease Reversed by Farnesol in Mice")
BioNTech's $325 million Series B financing proceeds will be used not only toward advancing its pipeline of immuno-oncology candidates, but adding to its manufacturing capacity and exploring an expanded global footprint as well . . .
Home Drug Discovery Antibodies BioNTech Boosting Pipeline, Manufacturing, Global Presence with $325M in Series B Financing
- Drug Discovery
- Antibodies
- Cancer
- Therapeutics
- Cellular Therapeutics
- Gastric Cancer
- GEN Edge
- Genome Editing
- Gene Therapy
- Head and Neck Cancer
- Immuno-oncology
- Immunotherapies
- Industry News
- Translational Medicine
- Infectious Diseases
- Monoclonal Antibodies
- RNA
- mRNA
- News
- OMICs
- Peptides
- Skin Cancer
